The appeals court decision has ensured that Novartis cannot bring its biosimilar Zarxio (filgrastim), which provides immune support to cancer patients, to the market at least till June 3.
A US appeals court has blocked Novartis AG from selling its knockoff version of an Amgen Inc. cancer supportive-care drug in the US until the court resolves a legal fight between the rivals.
The US Court of Appeals for the Federal Circuit in Washington on May 5 granted Amgen's request for an injunction blocking Novartis' Zarxio from the US market until the court resolves Amgen's appeal of a lower-court ruling that gave the green light to Zarxio's market entry.
The new order is expected to keep Zarxio off the US market at least until June 3, when oral arguments are scheduled, though resolution of the case could take longer.
Complete news on Nasdaq: http://bit.ly/1QsTGKK
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More